Beverage company The Calmer Co International (ASX:CCO) has reported its strongest single-month performance since listing on the ASX in 2018, with unaudited sales reaching $910,767 in December 2025.
The company's wholesale division achieved a record $340,131 for the month, with year-to-date sales already surpassing total wholesale revenue recorded in fiscal 2025.
Growth was broad-based across all channels, including Australian grocery, US Amazon, and B2B ingredient sales, reflecting improvements in channel mix and margin profile that support the company’s ongoing path to profitability.
Australian retail momentum was underpinned by strong distribution and sales of Fiji Kava through Coles and Woolworths, while US expansion benefited from an expanding Amazon product range following a recent US Food and Drug Administration confirmation that traditionally brewed kava beverages qualify as food under federal law.
Other product formats, including tinctures, capsules, and flavored kava shots, remain within the dietary supplement framework, aligning with the company's multi-format portfolio strategy.
Increased demand for high-kavalactone kava extracts from global partners also bolstered B2B ingredient sales.
Founder and CEO Zane Yoshida described the milestone as a defining achievement, emphasising the accelerating global demand for high-quality, traceable kava.
With over 21 million Americans now consuming kava, Yoshida highlighted the company's strong Australian grocery footprint, growing US dietary supplement portfolio, and expanding wholesale operations as key drivers for sustainable and profitable growth.
At the time of reporting, The Calmer Co International's share price was $0.0040.